LAS VEGAS, NV, Sept. 30, 2022 (GLOBE NEWSWIRE) — Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (“Company”, “Odyssey”) Focuses on The company has decided to dissolve its Sports Advisory Board by developing a proprietary drug to treat concussions.

The Sports Advisory Board has been an outspoken advocate of the importance of finding concussion prevention and responsible treatment. We created an advisory board to raise awareness of our mission to provide much-needed medicines for conditions for which there are currently no FDA-approved treatments. , completed a phase I clinical trial that proved our drug to be safe and well-tolerated. I am excited about the possibility of starting the trial.

The media misrepresents Odyssey Health, Inc. Odyssey has never received funding, directly or indirectly, from state or federal sources to fund drug development. Odyssey is not involved in any litigation. Odyssey Health, Inc. purchased the intellectual property and rights to this drug on March 1, 2021. Funding for the drug’s development came from accredited investors. We contacted the press and made factual and false reports.

To maintain our focus, the company has decided to dissolve the Sports Advisory Board. Odyssey intends to continue its focus on this important drug candidate in the hope that it will provide a much-needed treatment. We remain committed to bringing products to market that provide solutions to unmet medical needs.

About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a healthcare company focused on the area of ​​critical care solutions. Odyssey’s corporate mission is to create, acquire and develop unique assets, intellectual property and superior technology that deliver meaningful medical solutions. The company focuses on areas where it has identified technological advantages, offers superior clinical utility and has substantial market opportunity. For more information, please visit his website for the following companies: www.odysseyhealthinc.com.

About PRV-002
PRV-002 is a wholly synthetic, non-naturally occurring neurosteroid developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has shown comparable, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion have shown that PRV-002 attenuates behavioral pathologies associated with symptoms of brain injury such as memory impairment, anxiety and motor/sensory abilities. In addition, PRV-002 is lipophilic and readily crosses the blood-brain barrier to quickly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.

Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on our current expectations and are made only as of the date hereof.

inquiry:
odyssey health
info@odysseyhealthinc.com